Molecular Partners AG (MOLN) Key Metrics
MOLN key metrics, 2016–2025
Fiscal year ended December 31, 2025 · Swiss francsMOLN returns How much profit the business earns on the capital it uses.
MOLN financial health Debt, liquidity and how easily interest is covered.
MOLN efficiency & capital use Working capital cycle and where the cash goes.
MOLN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MOLN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MOLN cash returned to shareholders
MOLN key metrics in Swiss francs
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −55.5% | −34.0% | −30.1% | 68.8% | −59.5% | −77.8% | −49.8% | −35.5% | −20.1% | −12.9% |
| Return on assets (ROA) | −47.3% | −30.3% | −26.9% | 54.2% | −35.4% | −42.9% | −27.9% | −24.7% | −15.5% | −9.2% |
| Return on tangible assets | −60.4% | −34.1% | −31.3% | 45.0% | −37.0% | −33.5% | −34.8% | −23.9% | −17.6% | −10.1% |
| Free cash flow margin | — | — | −849.9% | 61.8% | −988.9% | −328.2% | −15.0% | −418.6% | −202.4% | −158.3% |
| Income quality (OCF / net income) | — | — | — | 1.01 | — | — | — | — | — | — |
| Financial health | ||||||||||
| Total debt | CHF 3.6M | CHF 2.4M | CHF 3.7M | CHF 4.8M | CHF 6.0M | CHF 7.2M | CHF 2.5M | — | — | — |
| Cash & short-term investments | CHF 93.1M | CHF 149.4M | CHF 186.9M | CHF 249.1M | CHF 132.8M | CHF 173.7M | CHF 95.1M | CHF 99.0M | CHF 141.1M | CHF 180.2M |
| Net debt | −CHF 89.4M | −CHF 147.0M | −CHF 183.2M | −CHF 244.3M | −CHF 126.8M | −CHF 166.5M | −CHF 92.5M | −CHF 99.0M | −CHF 141.1M | −CHF 180.2M |
| Debt / equity | 0.05 | 0.02 | 0.02 | 0.02 | 0.06 | 0.07 | 0.05 | — | — | — |
| Debt / assets | 0.04 | 0.02 | 0.02 | 0.02 | 0.03 | 0.04 | 0.02 | — | — | — |
| Net debt / EBITDA | — | — | — | −2.05 | — | — | — | — | — | — |
| Current ratio | 8.79 | 14.31 | 13.35 | 14.77 | 3.50 | 3.08 | 3.49 | 4.16 | 10.08 | 11.52 |
| Quick ratio | 8.79 | 14.31 | 13.35 | 14.77 | 3.50 | 3.09 | 3.51 | 4.22 | 10.75 | 11.57 |
| Interest coverage | — | — | — | 179.9 | -104.3 | -180.1 | -364.3 | -366.8 | -131.2 | -218.9 |
| Working capital | CHF 85.8M | CHF 143.5M | CHF 178.0M | CHF 237.5M | CHF 117.3M | CHF 120.1M | CHF 71.3M | CHF 116.5M | CHF 128.4M | CHF 165.8M |
| Invested capital | −CHF 9.1M | −CHF 5.4M | −CHF 6.8M | −CHF 9.1M | −CHF 19.5M | −CHF 59.3M | −CHF 38.4M | −CHF 7.3M | −CHF 24.3M | −CHF 44.4M |
| Tangible asset value | CHF 80.3M | CHF 141.6M | CHF 176.2M | CHF 234.9M | CHF 107.0M | CHF 106.9M | CHF 53.4M | CHF 91.3M | CHF 116.7M | CHF 135.7M |
| Net current asset value | CHF 75.1M | CHF 137.4M | CHF 170.5M | CHF 227.7M | CHF 98.8M | CHF 97.5M | CHF 49.1M | CHF 89.9M | CHF 114.8M | CHF 133.3M |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | CHF 250,000 | — | — | — | — | — | — |
| Share buybacks (net) | — | CHF 0 | CHF 3,000 | CHF 631,000 | CHF 0 | CHF 0 | — | — | — | — |
| Dividend payout ratio | — | — | — | 0.2% | — | — | — | — | — | — |
| Dividends + buybacks / free cash flow | — | — | — | 0.8% | — | — | — | — | — | — |
| Capex / revenue | — | 14.5% | 8.2% | 0.7% | 14.0% | 18.0% | 9.1% | 8.4% | 2.5% | 4.8% |
| Capex / operating cash flow | — | — | — | 1.2% | — | — | — | — | — | — |
| Capex / depreciation | 0.33 | 0.31 | 0.24 | 0.59 | 0.51 | 0.58 | 0.75 | 0.94 | 0.44 | 1.01 |
| Stock-based compensation / revenue | — | 82.6% | 74.0% | 2.7% | 43.8% | 31.4% | 12.0% | 35.9% | 18.0% | 12.4% |
| R&D / revenue | — | 977.9% | 693.2% | 26.8% | 597.2% | 600.1% | 213.4% | 368.9% | 187.1% | 152.7% |
| SG&A / revenue | — | 345.4% | 269.9% | 11.5% | 181.2% | 118.6% | 64.6% | 91.4% | 41.4% | 31.4% |
| Efficiency | ||||||||||
| Days sales outstanding | — | 123.7 | 124.0 | 26.4 | 558.7 | 105.2 | 485.0 | 930.0 | 18.2 | 17.3 |
| Days of inventory on hand | — | — | — | — | -0.7 | -2.2 | -11.7 | -137.2 | -105.2 | -9.0 |
| Days payables outstanding | 144.0 | 4.2 | 5.4 | 21.1 | 25.1 | 15.7 | 17.3 | 33.0 | 17.8 | 28.3 |
| Cash conversion cycle (days) | — | 119.6 | 118.6 | 5.3 | 533.0 | 87.3 | 456.0 | 759.8 | -104.9 | -19.9 |
| Receivables turnover | 0.00 | 2.95 | 2.94 | 13.82 | 0.65 | 3.47 | 0.75 | 0.39 | 20.05 | 21.06 |
| Payables turnover | 2.54 | 87.24 | 68.01 | 17.32 | 14.54 | 23.27 | 21.08 | 11.05 | 20.45 | 12.91 |
| Asset turnover | 0.00 | 0.03 | 0.03 | 0.87 | 0.05 | 0.06 | 0.16 | 0.07 | 0.12 | 0.11 |
| Average receivables | CHF 1.1M | CHF 1.7M | CHF 2.4M | CHF 13.7M | CHF 14.3M | CHF 2.7M | CHF 27.1M | CHF 26.4M | CHF 998,500 | CHF 1.1M |
| Average payables | CHF 808,000 | CHF 544,500 | CHF 703,500 | CHF 2.9M | CHF 3.8M | CHF 2.4M | CHF 2.1M | CHF 1.4M | CHF 871,500 | CHF 1.1M |
| Average inventory | — | — | — | — | −CHF 99,499 | −CHF 342,500 | −CHF 1.4M | −CHF 5.9M | −CHF 5.1M | −CHF 358,761 |
| Intangibles / total assets | 0.0% | 0.0% | 0.1% | 0.1% | 0.2% | 0.2% | 0.7% | 0.2% | 0.0% | 0.0% |
Computed from MOLN's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in Swiss francs; data from EODHD. Averages use the opening and closing balance of each year.
MOLN valuation and financial ratios
Molecular Partners earned a return on equity of −55.5% in fiscal 2025. It ended the year with CHF 3.6 million of debt and CHF 93.1 million in cash and short-term investments, a net cash position of CHF 89.4 million.
See the MOLN income statement, the MOLN chart for price history, or the MOLN stock overview for the latest quote and news.
MOLN key metrics FAQ
What is Molecular Partners's return on equity?
Molecular Partners's return on equity (ROE) was −55.5% in fiscal 2025: net income of -CHF 61.7 million on average shareholders' equity of CHF 111.0 million.
How much debt does Molecular Partners have?
Molecular Partners had total debt of CHF 3.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.05 and more cash than debt.
What is Molecular Partners's current ratio?
Molecular Partners's current ratio was 8.79 at the end of fiscal 2025: current assets were 8.79 times current liabilities.